newsfilter
← Latest News
PR Newswire·

Mirati To Encore Compelling Clinical Data Demonstrating Adagrasib's Potential as a Targeted Treatment for KRASG12C-Mutated Advanced Solid Tumors at 2023 ASCO Annual Meeting

Data follows recent inclusion of Adagrasib in NCCN Guidelines for PDAC and CNS Cancers Additional Company Presentations Highlight Real-World Observations in Patients Living with Metastatic NSCLC and KRASG12C Mutated